Business Wire

CGTN

8.3.2021 20:08:11 CET | Business Wire | Press release

Share
CGTN: Improving Hong Kong's Electoral System: What's at Stake?

China is mulling improving the electoral system of the Hong Kong Special Administrative Region (HKSAR) – but critics say it's a plan to eliminate opposition forces in the city.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005793/en/

Why are improvements imperative?

When explaining the draft decision on improving the electoral system of the HKSAR to lawmakers, Wang Chen, vice chairman of the National People's Congress (NPC) Standing Committee, said the move is to prevent anti-China, destabilizing forces from seizing power, citing the months-long riots in 2019.

"To remedy the situation, it is important to take necessary steps to improve the electoral system and remove existing institutional deficiencies and risks to ensure the administration of Hong Kong by Hong Kong people with patriots as the main body," Wang said.

Alex Fan, founding president of the International Youth Legal Exchange Federation in Hong Kong, told CGTN that "allowing non-patriots or even people endangering national security to participate in the election will put the 'One Country, Two Systems' in peril."

What can be improved?

According to the draft decision, the focus of the improvements will be on the reform and greater empowerment of the city's Election Committee.

"Hong Kong's chief executive will continue to be elected by the Election Committee. The committee will also elect a relatively large share of Legislative Council (LegCo) members and directly participate in the nomination of all LegCo candidates," Wang said, adding that the revisions to be made may be limited to Annex I and Annex II to the Basic Law, without revising the main body of the Basic Law.

How will it be carried out?

A two-step approach, namely, "decision plus amendment," has been put forward. The NPC, China's top legislature, first makes a decision on improving the electoral system of the HKSAR and authorizes its Standing Committee to amend. Then the NPC Standing Committee amends the Annex I and Annex II to the Basic Law of the HKSAR.

After the amendment at the state level is completed, the HKSAR will amend relevant local laws accordingly.

In consideration of the complexity of Hong Kong's election-related local laws, experts believe the process will take some time but will be completed before elections in Hong Kong in the second half of the year.

What would the improvements mean?

Li Huan, an associate research fellow at the Hong Kong and Macao Research Center, rejected concerns that the non-establishment camp in Hong Kong would have no room to participate in politics after the amendment, saying the decision "does not aim to serve the pro-establishment camp or to restrict the non-establishment camp."

"It depends on how one understands the non-establishment camp. People from the non-establishment camp are not necessarily unpatriotic or those who don't love Hong Kong," Li told CGTN.

This echoed the words of Xia Baolong, vice chairman of the National Committee of the Chinese People's Political Consultative Conference and head of the Hong Kong and Macao Affairs Office of the State Council, who has said the emphasis on "patriots governing Hong Kong" is not meant to erase all differences.

Liu Zhaojia, the vice chairman of the National Hong Kong and Macao Research Association, added: "Pro-establishment candidates can also rest easy. They must put in real efforts to solve Hong Kong's social and livelihood problems in order to gain a better political future."

The Liaison Office of the HKSAR voiced support for improving the electoral system, stating "it is the only way for Hong Kong society to end political disputes, refocus on development and protect the long-term prosperity and stability."

The HKSAR delegation to the Two Sessions said the proposed improvements would not make any change to "One Country, Two Systems," but would strengthen the principle, as well as put an end to the political chaos in Hong Kong and allow local society to focus on economic development, people's livelihood and the SAR's integration into the overall development of the country.

No one cares more about Hong Kong's democracy and continued prosperity and stability than the Central Government of China, Chinese State Councilor and Foreign Minister Wang Yi stated on Sunday, adding that Hong Kong's shift from chaos to stability serves the interests of all parties.

https://news.cgtn.com/news/2021-03-08/Improving-Hong-Kong-s-electoral-system-What-s-at-stake--YstxU8LeKs/index.html

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release

Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S

Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release

Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release

OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye